Sofosbuvir-velpatasvir successful in hep C regardless of genotype

November 18, 2015
Sofosbuvir-velpatasvir successful in hep C regardless of genotype

(HealthDay)—Sofosbuvir-velpatasvir is effective for hepatitis C virus (HCV), regardless of genotype, according to three studies published online Nov. 17 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Association for the Study of Liver Diseases, held from Nov. 13 to 17 in San Francisco.

Jordan J. Feld, M.D., M.P.H., from the Toronto Western Hospital Liver Centre, and colleagues conducted a phase 3 study involving with HCV genotypes 1, 2, 4, 5, or 6, who were randomized to receive sofosbuvir and velpatasvir or matching placebo. The researchers found that among the 624 patients receiving sofosbuvir-velpatasvir, the rate of sustained virologic response was 99 percent at 12 weeks after the end of therapy; two patients had a virologic relapse.

Michael P. Curry, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues conducted a phase 3 study involving 267 patients with HCV genotypes 1 through 6 who had decompensated cirrhosis. Participants were randomized to 12 weeks of sofosbuvir-velpatasvir or sofosbuvir-velpatasvir plus ribavirin, or to 24 weeks of sofosbuvir-velpatasvir. The researchers found that the overall sustained virologic response was 83, 94, and 86 percent, respectively, with no significant between-group differences. In a third study, Graham R. Foster, Ph.D., from the Queen Mary University of London, and colleagues found that 12 weeks of sofosbuvir-velpatasvir treatment resulted in superior rates of sustained virologic versus sofosbuvir-ribavirin among patients with HCV genotype 2 or 3.

"These studies indicate that this drug regimen can achieve high rates of HCV cure regardless of ," write the authors of an accompanying editorial.

All three studies were funded by Gilead Sciences, the manufacturer of sofosbuvir-velpatasvir.

Explore further: Sofosbuvir plus ledipasvir seems effective for HCV genotype 1

More information: Abstract - Feld
Full Text
Abstract - Curry
Full Text
Abstract - Foster
Full Text
Editorial
More Information

Related Stories

Sofosbuvir plus ledipasvir seems effective for HCV genotype 1

November 4, 2014
(HealthDay)—For patients with chronic hepatitis C virus genotype 1 (HCV GT-1) infection who are ineligible for interferon therapy, and who relapsed after sofosbuvir and ribavirin treatment, sofosbuvir plus ledipasvir is ...

Sofosbuvir shows promise for chronic hepatitis C infection

April 23, 2013
(HealthDay)—Sofosbuvir seems to be a promising treatment option for patients with chronic hepatitis C virus (HCV) infection, according to two studies published online April 23 in the New England Journal of Medicine to coincide ...

Sofosbuvir plus peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients

April 25, 2015
Results presented today at The International Liver Congress 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ...

Interferon-free therapies for hep C virus look promising

January 3, 2013
(HealthDay)—For untreated patients with hepatitis C virus (HCV), treatment with an oral nucleotide inhibitor of HCV polymerase, sofosbuvir, plus ribavirin seems effective for genotypes 1, 2, and 3; and the HCV NS3 protease ...

All-oral, DAA options for HCV effective and well tolerated in patients with decompensated cirrhosis

April 23, 2015
Interim data presented today at The International Liver Congress 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients ...

Ledipasvir-sofosbuvir combination proves effective in subset of patients with chronic hepatitis C

April 24, 2015
A new study presented today at The International Liver Congress 2015 has demonstrated that ledipasvir (LDV) in combination with sofosbuvir (SOF) achieves sustained virologic response rates 12 weeks after treatment (SVR12; ...

Recommended for you

Zika virus stifles pregnant women's weakened immune system to harm baby, study finds

August 21, 2017
The Zika virus, linked to congenital birth defects and miscarriages, suppresses a pregnant woman's immune system, enabling the virus to spread and increasing the chances an unborn baby will be harmed, a Keck School of Medicine ...

Fatty liver can cause damage to other organs via crosstalk

August 21, 2017
Nonalcoholic fatty liver disease is increasingly common. Approximately every third adult in industrialized countries has a morbidly fatty liver. This not only increases the risk of chronic liver diseases such as liver cirrhosis ...

Faulty gene linked to obesity in adults

August 18, 2017
Groundbreaking new research linking obesity and metabolic dysfunction to a problem in the energy generators in cells has been published by researchers from the Harry Perkins Institute of Medical Research and The University ...

Two lung diseases killed 3.6 million in 2015: study

August 17, 2017
The two most common chronic lung diseases claimed 3.6 million lives worldwide in 2015, according to a tally published Thursday in The Lancet Respiratory Medicine.

New test differentiates between Lyme disease, similar illness

August 16, 2017
Lyme disease is the most commonly reported vector-borne illness in the United States. But it can be confused with similar conditions, including Southern Tick-Associated Rash Illness. A team of researchers led by Colorado ...

Addressing superbug resistance with phage therapy

August 16, 2017
International research involving a Monash biologist shows that bacteriophage therapy – a process whereby bacterial viruses attack and destroy specific strains of bacteria - can be used successfully to treat systemic, multidrug ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.